Side effects across medicines
Medicines whose labels list common cold symptoms
322 medicines have an FDA label that names common cold symptoms (nasopharyngitis) in its boxed warning, warnings, adverse reactions, trial table, patient leaflet or Drug Facts “stop use” warning (of the labels PlainMeds reads: each medicine's quoted label and up to eight more, by route and wording). Among them, the most FAERS reports of common cold symptoms name adalimumab (20,883), etanercept (20,841) and methotrexate (15,472), through July 30, 2026. A label lists what its studies and reports found, and a report does not show that a medicine caused the event.
Check it at the source: the FDA FAERS public dashboard; FDA labels on DailyMed.
Which medicines' labels list common cold symptoms?
Ordered by where the label names it, the boxed warning first, then by FAERS reports. The first 150 of the 322 are below; every other one is on its medicine record. A medicine whose own indications name it, because it treats it, is not counted.
| Medicine | Where a label names it | FAERS reports of common cold symptoms |
|---|---|---|
| Inebilizumab | warnings and precautions | none in the top 1,000 |
| Adalimumab | adverse reactions | 20,883 |
| Etanercept | adverse reactions | 20,841 |
| Methotrexate | adverse reactions (subcutaneous label) | 15,472 |
| Tofacitinib | adverse reactions | 8,920 |
| Secukinumab | adverse reactions | 7,818 |
| Tocilizumab | adverse reactions | 7,488 |
| Rituximab | adverse reactions | 6,939 |
| Abatacept | adverse reactions | 6,864 |
| Dupilumab | adverse reactions | 6,839 |
| Certolizumab | adverse reactions | 6,213 |
| Lenalidomide | adverse reactions | 4,865 |
| Pregabalin | adverse reactions | 4,529 |
| Natalizumab | adverse reactions | 4,481 |
| Celecoxib | adverse reactions | 4,254 |
| Omalizumab | adverse reactions | 3,986 |
| Ustekinumab | adverse reactions | 3,665 |
| Apremilast | adverse reactions | 3,353 |
| Atorvastatin | adverse reactions | 3,194 |
| Budesonide and formoterol | adverse reactions | 2,808 |
| Evolocumab | adverse reactions | 2,599 |
| Vedolizumab | adverse reactions | 2,512 |
| Adalimumab-fkjp | adverse reactions | 2,368 |
| Adalimumab-aaty | adverse reactions | 2,363 |
| Mepolizumab | adverse reactions | 2,241 |
| Fluticasone and salmeterol | adverse reactions | 2,151 |
| Tadalafil | adverse reactions | 2,057 |
| Insulin glargine | adverse reactions | 1,850 |
| Macitentan | adverse reactions | 1,755 |
| Sarilumab | adverse reactions | 1,754 |
| Escitalopram | adverse reactions | 1,653 |
| Upadacitinib | adverse reactions | 1,592 |
| Mesalamine | adverse reactions | 1,526 |
| Palbociclib | adverse reactions | 1,377 |
| Denosumab | adverse reactions | 1,357 |
| Risankizumab | adverse reactions | 1,349 |
| Eculizumab | adverse reactions | 1,334 |
| Ofatumumab | adverse reactions | 1,269 |
| Tramadol | adverse reactions | 1,208 |
| Mirabegron | adverse reactions | 1,147 |
| Octreotide | adverse reactions (oral label) | 1,097 |
| Estradiol | adverse reactions (topical label) | 1,073 |
| Ciclesonide | adverse reactions | 1,037 |
| Golimumab | adverse reactions | 1,037 |
| Valacyclovir | adverse reactions | 981 |
| Duloxetine | adverse reactions | 935 |
| Dalfampridine | adverse reactions | 907 |
| Ezetimibe | adverse reactions | 896 |
| Ibrutinib | adverse reactions | 877 |
| Sitagliptin | adverse reactions | 875 |
| Fluticasone and vilanterol | adverse reactions | 836 |
| Bosentan | adverse reactions | 780 |
| Ruxolitinib | adverse reactions (topical label) | 774 |
| Dexlansoprazole | adverse reactions | 748 |
| Buprenorphine | adverse reactions (transdermal label) | 741 |
| Levetiracetam | adverse reactions | 702 |
| Methylphenidate | adverse reactions | 672 |
| Nintedanib | adverse reactions | 649 |
| Ixekizumab | adverse reactions | 645 |
| Botulinum toxin type a | adverse reactions | 643 |
| Aripiprazole | adverse reactions | 608 |
| Insulin aspart | adverse reactions | 571 |
| Trastuzumab | adverse reactions | 564 |
| Fluticasone and umeclidinium and vilanterol | adverse reactions | 543 |
| Belimumab | adverse reactions | 532 |
| Metronidazole | adverse reactions (topical label) | 524 |
| Everolimus | adverse reactions | 512 |
| Niraparib | adverse reactions | 458 |
| Glatiramer | adverse reactions | 456 |
| Bimekizumab | adverse reactions | 420 |
| Pancrelipase amylase and pancrelipase lipase and pancrelipase protease | adverse reactions | 404 |
| Enzalutamide | adverse reactions | 395 |
| Trofinetide | adverse reactions | 383 |
| Peginterferon alfa 2a | adverse reactions | 379 |
| Risperidone | adverse reactions | 377 |
| Fulvestrant | adverse reactions | 375 |
| Alemtuzumab | adverse reactions | 364 |
| Olanzapine | adverse reactions | 358 |
| Progesterone | adverse reactions | 356 |
| Nilotinib | adverse reactions | 322 |
| Anakinra | adverse reactions | 305 |
| Liraglutide | adverse reactions | 300 |
| Cabozantinib | adverse reactions | 295 |
| Pertuzumab | adverse reactions | 291 |
| Nivolumab | adverse reactions | 280 |
| Mycophenolic acid | adverse reactions | 279 |
| Dapagliflozin | adverse reactions | 273 |
| Ravulizumab | adverse reactions | 260 |
| Guselkumab | adverse reactions | 259 |
| Formoterol and mometasone | adverse reactions | 253 |
| Sunitinib | adverse reactions | 253 |
| Canakinumab | adverse reactions | 244 |
| Imatinib | adverse reactions | 243 |
| Teduglutide | adverse reactions | 227 |
| Ivacaftor and lumacaftor | adverse reactions | 202 |
| Carfilzomib | adverse reactions | 195 |
| Budesonide and formoterol and glycopyrrolate | adverse reactions | 181 |
| Deflazacort | adverse reactions | 181 |
| Isotretinoin | adverse reactions | 179 |
| Umeclidinium | adverse reactions | 179 |
| Metformin and sitagliptin | adverse reactions | 174 |
| Ivacaftor | adverse reactions | 171 |
| Eltrombopag | adverse reactions | 169 |
| Aclidinium | adverse reactions | 162 |
| Testosterone | adverse reactions (topical label) | 153 |
| Linagliptin | adverse reactions | 148 |
| Vigabatrin | adverse reactions | 145 |
| Formoterol | adverse reactions | 143 |
| Ropinirole | adverse reactions | 142 |
| Ranibizumab | adverse reactions | 141 |
| Abiraterone | adverse reactions | 127 |
| Colesevelam | adverse reactions | 126 |
| Dabrafenib | adverse reactions | 124 |
| Rucaparib camsylate | adverse reactions | 122 |
| Eptinezumab | adverse reactions | 119 |
| Hydrochlorothiazide and valsartan | adverse reactions | 119 |
| Brimonidine | adverse reactions (topical label) | 113 |
| Baricitinib | adverse reactions | 110 |
| Tapentadol | adverse reactions | 108 |
| Adalimumab-afzb | adverse reactions | 102 |
| Betamethasone and calcipotriene | adverse reactions | 98 |
| Pitavastatin | adverse reactions | 98 |
| Ozanimod | adverse reactions | 97 |
| Rifaximin | adverse reactions | 97 |
| Lurasidone | adverse reactions | 93 |
| Vibegron | adverse reactions | 91 |
| Selinexor | adverse reactions | 85 |
| Ipilimumab | adverse reactions | 84 |
| Olaparib | adverse reactions | 82 |
| Insulin glulisine | adverse reactions | 79 |
| Hydrocodone | adverse reactions | 78 |
| Bosutinib | adverse reactions | 75 |
| Phentermine and topiramate | adverse reactions | 75 |
| Ublituximab | adverse reactions | 75 |
| Olopatadine | adverse reactions (nasal label) | 73 |
| Tezepelumab | adverse reactions | 72 |
| Dapsone | adverse reactions (topical label) | 71 |
| Lomitapide | adverse reactions | 71 |
| Valganciclovir | adverse reactions | 71 |
| Iron sucrose | adverse reactions | 70 |
| Abemaciclib | adverse reactions | none in the top 1,000 |
| Abrocitinib | adverse reactions | none in the top 1,000 |
| Acalabrutinib | adverse reactions | none in the top 1,000 |
| Adalimumab-aacf | adverse reactions | none in the top 1,000 |
| Adalimumab-adbm | adverse reactions | none in the top 1,000 |
| Adalimumab-ryvk | adverse reactions | none in the top 1,000 |
| Aflibercept | adverse reactions (intravenous label) | none in the top 1,000 |
| Albuterol and budesonide | adverse reactions | none in the top 1,000 |
| Alogliptin | adverse reactions | none in the top 1,000 |
| Alogliptin and metformin | adverse reactions | none in the top 1,000 |
Source: FDA drug labels via openFDA, read October 8, 2026; FAERS via openFDA, reports through July 30, 2026
Which of them have the most common cold symptoms reports in FAERS?
Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; MedDRA preferred term “Nasopharyngitis”
What next?
- Side effects across medicines
- every reaction on PlainMeds
- Report a side effect to the FDA
- MedWatch